薄芝糖肽联合美洛西林钠舒巴坦钠对脑血管病后遗症患者社区获得性肺炎的临床疗效观察

Clinical efficacy of Bozhi glycopeptide combined with mezlocillin sodium and sulbactam sodium on community-acquired pneumonia in patients with cerebrovascular disease sequelae

关键词:  薄芝糖肽  美洛西林钠舒巴坦钠  脑血管病后遗症  肺炎

Key words:  Bozhi glycopeptide  mezlocillin sodium sulbactam sodium  cerebrovascular sequelae  pneumonia

摘要:

目的 探讨薄芝糖肽联合美洛西林钠舒巴坦钠治疗脑血管后遗症患者社区获得性肺炎的疗效。方法 将天津市西青医院呼吸科2016年1月至2018年1月收治的96例脑血管后遗症肺炎患者作为研究对象，随机分为对照组和观察组，每组48例。其中对照组采用美洛西林钠舒巴坦钠进行治疗，观察组采用薄芝糖肽联合美洛西林钠舒巴坦钠进行治疗，对两组临床效果进行观察。结果 观察组治愈率50.0%，总有效率93.75%，对照组治愈率39.58%，总有效率81.25%，两组比较差异具有统计学意义（P<0.05）。两组治疗结束后WBC、PCT组间比较差异有统计学意义（P<0.05）；在咳嗽停止时间、体温恢复正常时间、住院天数方面，观察组比对照组明显缩短（P<0.05）。结论 薄芝糖肽联合美洛西林钠舒巴坦钠可提高脑血管后遗症伴社区获得性肺炎患者的临床疗效，近期治疗效果较好，未发现明显的副作用，值得临床推广。

Abstract:

Objective To evaluate the efficacy of Bozhi glycopeptide combined with meloxicillin sodium and sulbactam in the treatment of community-acquired pneumonia in patients with cerebral vascular sequelae. Methods A total of 96 cerebrovascular sequelae patients with pneumonia in Tianjin Xiqing Hospital from January 2016 to January 2018 were enrolled in the study. They were randomly divided into two groups (n=48 in each group). The patients in the control group were treated with mezlocillin sodium and sulbactam sodium; the patients in the treatment group received Bozhi glycopeptide combined with meloxicillin sodium and sulbactam sodium. Results The cure rate in the treatment group was 50.0% with a total effective rate of 93.75%, whereas the cure rate and total effective rate in the control group were 39.58% and 81.25%, respectively. There was significant difference between the two groups (P<0.05). Compared to the control group, the cough duration, body temperature recovery time and hospitalization days were significantly reduced in the treatment group (P<0.05). The number of re-infection patients during the follow-up period in the treatment group was slightly less than that in the control group although no statistical difference was observed. Conclusion Bozhi glycopeptide combined with mezlocillin sodium and sulbactam sodium can improve the cure rate with good short-term treatment effect and no obvious side effects, and is worthily recommended in the clinical application.